Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Syros Pharmaceuticals, Inc. (NASDAQ: SYRS).

Full DD Report for SYRS

You must become a subscriber to view this report.


Recent News from (NASDAQ: SYRS)

Syros Announces Promising Clinical Data from Ongoing Phase 2 Trial of SY-1425 in Genomically Defined AML and MDS Patients at ASH Annual Meeting
SY-1425 in Combination with Azacitidine Shows 63% Overall Response Rate and Rapid Onset of Clinical Responses in RARA or IRF8 Biomarker-Positive Newly Diagnosed Unfit AML Patients Initial Data from Biomarker-Positive and -Negative Azacitidine Combination Cohorts Support Potential Predi...
Source: Business Wire
Date: December, 02 2018 12:01
Syros to Present at 30th Annual Piper Jaffray Healthcare Conference
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the 30 th Annual Piper Jaffray Healthcare Conference. Details a...
Source: Business Wire
Date: November, 20 2018 08:01
Morgan Stanley upgrades Teva and Bausch in premarket analyst action
Fate Therapeutics (NASDAQ: FATE ) initiated with Buy rating and $17 (15% upside) at Jefferies. More news on: Fate Therapeutics, Inc., Allogene Therapeutics, Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: November, 05 2018 08:47
Syros Pharmaceuticals, Inc. (SYRS) CEO Dr. Nancy Simonian on Q3 2018 Results - Earnings Call Transcript
Syros Pharmaceuticals, Inc. (SYRS) Q3 2018 Results Earnings Conference Call November 01, 2018 07:30 AM ET Executives Naomi Aoki - VP, Corporate Communications and IR Dr. Nancy Simonian - CEO Dr. David Roth - Chief Medical Officer Dr. Eric Olson - Chief Scientific Officer Joe ...
Source: SeekingAlpha
Date: November, 03 2018 16:03
Syros to Present Initial Clinical Data from Combination Cohorts in Its Ongoing Phase 2 Trial of SY-1425 at ASH Annual Meeting
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that the Company will present initial clinical data from both combination cohorts in its ongoing Phase 2 trial of SY-1425, its first-in-class selective retinoi...
Source: Business Wire
Date: November, 01 2018 09:01
Syros Pharmaceuticals misses by $0.01, misses on revenue
Syros Pharmaceuticals (NASDAQ: SYRS ): Q3 GAAP EPS of -$0.47 misses by $0.01 . More news on: Syros Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: November, 01 2018 07:10
Syros Reports Third Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Opened Expansion Cohorts in Phase 1 Trial Evaluating SY-1365 in Multiple Ovarian and Breast Cancer Populations as Single Agent and in Combination Selected Oral CDK7 Inhibitor SY-5609 as Development Candidate to Enter IND-Enabling Studies Dose Escalation Data from Phase 1 Trial of ...
Source: Business Wire
Date: November, 01 2018 07:00
Syros to Present Clinical and Preclinical Data on SY-1365 and Earlier-Stage Pipeline at EORTC-NCI-AACR Meeting
First Clinical Data from Phase 1 Trial of SY-1365 in Advanced Solid Tumors to be Highlighted in Oral Plenary Session Preclinical Data on Oral CDK7 Inhibitor Program to be Unveiled in Poster Session Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines tha...
Source: Business Wire
Date: October, 30 2018 07:01
Syros to Report Third Quarter 2018 Financial Results on Thursday, November 1, 2018
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines to control the expression of genes, today announced that it will host a live conference call and webcast at 7:30 a.m. ET on Thursday, November 1, 2018 to report its third quarter 2018 financial ...
Source: Business Wire
Date: October, 25 2018 07:30
Syros to Present at Morgan Stanley 16th Annual Global Healthcare Conference
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the Morgan Stanley 16th Annual Global...
Source: Business Wire
Date: September, 06 2018 08:01

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-1411.9212.2812.3511.90107,413
2017-03-1011.999912.0012.0011.951,340
2017-03-0911.09911.9112.0011.0425,566
2017-03-0811.1411.0011.2410.9720,159
2017-03-0711.1211.0411.2110.8318,977

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-078,07212,63763.8759Short
2018-12-067,63216,09347.4243Short
2018-12-0420,33437,89353.6616Short
2018-12-0321,581109,40919.7251Cover
2018-11-308,75214,04962.2962Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SYRS.


About Syros Pharmaceuticals, Inc. (NASDAQ: SYRS)

Logo for Syros Pharmaceuticals, Inc. (NASDAQ: SYRS)

Not available

 

Contact Information

 

 

Current Share Structure

     


    Recent Filings from (NASDAQ: SYRS)

    Amendment to a previously filed 10-K
    Filing Type: 10-K/AFiling Source: edgar
    Filing Date: August, 24 2018
    Amendment to a previously filed 10-Q
    Filing Type: 10-Q/AFiling Source: edgar
    Filing Date: August, 24 2018
    Amendment to a previously filed 10-Q
    Filing Type: 10-Q/AFiling Source: edgar
    Filing Date: August, 24 2018
    Quarterly report with a continuing view of a company's financial position
    Filing Type: 10-QFiling Source: edgar
    Filing Date: August, 07 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: June, 15 2018
    Quarterly report with a continuing view of a company's financial position
    Filing Type: 10-QFiling Source: edgar
    Filing Date: May, 10 2018
    Official notification to shareholders of matters to be brought to a vote (Proxy)
    Filing Type: DEF 14AFiling Source: edgar
    Filing Date: April, 26 2018
    Additional proxy soliciting materials - definitive
    Filing Type: DEFA14AFiling Source: edgar
    Filing Date: April, 26 2018
    Filing Type: CT ORDERFiling Source: edgar
    Filing Date: April, 24 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: March, 15 2018

     

     


    Daily Technical Chart for (NASDAQ: SYRS)

    Daily Technical Chart for (NASDAQ: SYRS)


    Stay tuned for daily updates and more on (NASDAQ: SYRS)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: SYRS)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SYRS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of SYRS and does not buy, sell, or trade any shares of SYRS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/